Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months

Next Previous
Trial Profile

A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms ASTEROID 1
  • Sponsors Bayer

    • Most Recent Events

    • 30 Jul 2021 Results assessing exposure response modelling and simulation data of vilaprisan efficacy by using data from phase I and 2 studies including this study published in the British Journal of Clinical Pharmacology
    • 06 Dec 2018 Results published in the Fertility and Sterility
    • 10 Oct 2018 Results of an integrated analysis of ASTEROID 1 and 2 studies aimed to assess the efficacy and safety of vilaprisan in women with uterine fibroids using an extended patient dataset, presented at the American Society for Reproductive Medicine Scientific Congress 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top